Browse drugs

…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…

… of patients, and 12.5% had CNS metastases. Treatments included pembrolizumab (71.9%), nivolumab (21.9%) and durvalumab (6.3%); 71.9% receive…

…gical therapy (21%), and other (9%). Most implicated drugs were nivolumab, ipilimumab, carboplatin, paclitaxel, oxaliplatin, and pembroli…

…f care (26.3%). 31.5% of patients required a dose adjustment of binimetinib, and 21% discontinued treatment, with only one discontinuation …

…0 (95% CI, 0.45-0.81; p=0.0009) between EV-Pembrolizumab versus Nivolumab-CT. According to the ATE guide, these treatments presented a degre…

…s with rare cancers treated with dual checkpoint blockade using ipilimumab plus nivolumab, based on data from 52 baskets in the DART SWOG …

… 70s with metastatic melanoma being treated with ipilimumab and nivolumab. He presented with febrile neutropenia after lacerating a thumb…

…umab (360 mg intravenously every 3 weeks) and cohort B received hydroxychloroquine (600 mg orally two times a day). The primary endpoint was safet…

…programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma w…

…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…

…dence base is compatible with a favourable effect of first-line nivolumab plus ipilimumab for adults with untreated metastatic BRAF-mutan…

…0–2, aged ≥18 years were eligible. Participants received 480 mg nivolumab every 28 days for up to 24 cycles. The primary outcome was dura…